EP4716744A2 - Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5 - Google Patents

Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5

Info

Publication number
EP4716744A2
EP4716744A2 EP24811929.9A EP24811929A EP4716744A2 EP 4716744 A2 EP4716744 A2 EP 4716744A2 EP 24811929 A EP24811929 A EP 24811929A EP 4716744 A2 EP4716744 A2 EP 4716744A2
Authority
EP
European Patent Office
Prior art keywords
cell
cancer
antigen binding
gene
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24811929.9A
Other languages
German (de)
English (en)
Inventor
Nicholas A. Siciliano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vittoria Biotherapeutics Inc
Original Assignee
Vittoria Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vittoria Biotherapeutics Inc filed Critical Vittoria Biotherapeutics Inc
Publication of EP4716744A2 publication Critical patent/EP4716744A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Les modes de réalisation concernent des cellules comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un locus de gène CD5. L'invention concerne également des compositions comprenant lesdites cellules, ainsi que des méthodes de fabrication et d'utilisation desdites cellules et desdites compositions.
EP24811929.9A 2023-05-23 2024-05-23 Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5 Pending EP4716744A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503809P 2023-05-23 2023-05-23
PCT/US2024/030831 WO2024243436A2 (fr) 2023-05-23 2024-05-23 Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5

Publications (1)

Publication Number Publication Date
EP4716744A2 true EP4716744A2 (fr) 2026-04-01

Family

ID=93590466

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24811929.9A Pending EP4716744A2 (fr) 2023-05-23 2024-05-23 Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5

Country Status (4)

Country Link
EP (1) EP4716744A2 (fr)
KR (1) KR20260051108A (fr)
CN (1) CN121844048A (fr)
WO (1) WO2024243436A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132327A1 (fr) * 2018-12-19 2020-06-25 The Trustees Of The University Of Pennsylvania Utilisation de lymphocytes t de récepteur antigénique chimérique anti-cd2/5/7 à cd2/5/7 inactivé dirigés contre des lymphomes et des leucémies à lymphocytes t
US20240041932A1 (en) * 2020-09-14 2024-02-08 Vor Biopharma Inc. Compositions and methods for cd5 modification

Also Published As

Publication number Publication date
CN121844048A (zh) 2026-04-10
WO2024243436A2 (fr) 2024-11-28
WO2024243436A3 (fr) 2025-04-24
KR20260051108A (ko) 2026-04-15

Similar Documents

Publication Publication Date Title
AU2023201620C1 (en) CAR T cell therapies with enhanced efficacy
US20230312677A1 (en) Cd28 compositions and methods for chimeric antigen receptor therapy
US20250368750A1 (en) Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20260078341A1 (en) Treatment of cancer using chimeric antigen receptor
US20200215171A1 (en) Treatment of cancer using a cll-1 chimeric antigen receptor
US12128069B2 (en) Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP2023082071A (ja) 増強された有効性を有するバイオマーカー及びｃａｒ ｔ細胞療法
US20200339651A1 (en) Methods for b cell preconditioning in car therapy
EP3784351A1 (fr) Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
US20180092968A1 (en) Compositions to disrupt protein kinase a anchoring and uses thereof
WO2016014576A1 (fr) Traitement du cancer à l'aide du récepteur antigénique chimérique anti-cd33
US20250163148A1 (en) Anti-car compositions and methods
US20200390811A1 (en) Compositions to disrupt protein kinase a anchoring and uses thereof
WO2024243436A2 (fr) Cellules génétiquement modifiées comprenant une molécule d'acide nucléique hétérologue insérée au niveau d'un champ de locus de gène cd5

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR